5j yang lalu
Unichain Hands Production Operations to Optimism's OP Enterprise, Mainnet Migration Set for October 29
Unichain, Uniswap's Layer 2 network, is moving its production operations to Optimism's OP Enterprise stack, according to Uniswap. The testnet migrates on October 13, with the mainnet following on October 29. The chain ID, deployed contracts, user balances and application state stay unchanged, and the Uniswap v2, v3 and v4 deployments are unaffected. Once interoperability goes live, assets will move directly between Unichain and other OP Stack chains without a bridge, starting with ETH; direct user benefits await that rollout.
OP
OP-2.11%
5j yang lalu
5j yang lalu
High-Stakes Earnings Season Puts AI Stocks to the Test
The market's most expensive stocks, measured by forward price-to-earnings ratios at the end of the second quarter, suffered unusually sharp valuation contraction in the third quarter, according to Trivariate Research. Their multiple compression was roughly 100 times as large as that of the cheapest names, an extreme seen only 5.3% of the time since 1999. AI capital-spending-sensitive high-valuation names such as AMD, Marvell, Corning and Bloom Energy were hit hardest. The S&P 500's forward price-to-earnings ratio fell to 19 at the end of last week from 22 at the start of 2026.
5j yang lalu
5j yang lalu
ETF Australia tembus rekor $388 miliar, perubahan CGT percepat arus masuk
Industri ETF Australia mencatat rekor aset $388,1 miliar, tumbuh 25,5 persen dibandingkan setahun sebelumnya. Arus masuk bersih pada September mencapai $6,9 miliar dan mengerek total investasi kuartalan ke rekor $21 miliar. Strategi berbasis indeks menjadi pendorong utama dengan serapan $5,9 miliar pada September, sekitar 85 persen dari total arus masuk bulan itu. ETF emas juga membukukan arus masuk rekor $682 juta pada kuartal September, sementara reformasi pajak keuntungan modal pemerintah federal mempercepat tren ini.
5j yang lalu
5j yang lalu
Saham CSL, Westpac, dan BHP: mana yang layak dibeli, ditahan, atau dijual?
CSL menandatangani perjanjian lisensi eksklusif dengan Alentis Therapeutics untuk memperoleh hak global atas lixudebart, obat bagi penyakit ginjal dan hati langka. Nilai transaksi mencapai US$1,6 miliar, mencakup pembayaran awal US$355 juta dan pembayaran milestone komersial hingga US$1,2 miliar. Meski mayoritas broker memberi peringkat beli, harga target rata-rata saat ini sebesar US$159,86 menyiratkan potensi penurunan sekitar 14%.
5j yang lalu